A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00597519
First received: December 26, 2007
Last updated: September 18, 2013
Last verified: September 2013
  Purpose

In this study two cord blood collections will be used to increase the number of cord blood cells you will receive on transplant day. We call this a "double unit" cord blood transplant. A previous study suggests double unit cord blood transplant may have a better result. The main purpose of this study is to find out how good a cord blood transplant using two cord blood collections from two different babies is at curing you of your cancer. Double unit cord blood transplants are now being studied as a way to increase the number of cord blood cells given to bigger children and adult patients.

Based on studies that have already been done double unit cord blood transplant appears to be safer than if only one cord blood unit is used. However, double unit cord blood transplant is a fairly new form of treatment.


Condition Intervention Phase
Cancer
Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Drug: Fludarabine, Cyclophosphamide
Procedure: Transplantation
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Myeloablative Conditioning Regimen Consisting of Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients With Hematological Malignancy.

Resource links provided by NLM:


Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • To obtain a preliminary estimate of efficacy of double unit UCBT as measured by overall and disease-free survival at 1 year. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The incidence and rate of donor derived neutrophil and platelet recovery; the contribution of each unit to initial and sustained engraftment; the incidence and severity of acute GVHD at 100 days [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 55
Study Start Date: March 2006
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Patients with hematopoietic malignancy at high-risk for relapse or with advanced disease will receive myeloablative conditioning with cyclophosphamide (Cy), low dose fludarabine (Flu) and total body irradiation (TBI) with post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.
Drug: Fludarabine, Cyclophosphamide

Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.

Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).

Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery.

Procedure: Transplantation
The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.

Detailed Description:

This is a single arm phase 2 study to obtain a preliminary estimate of efficacy of myeloablative double unit umbilical cord blood transplantation (UCBT) as measured by overall and disease-free survival at 1 year post transplantation. The UCB graft will consist of two (or double) units from two unrelated newborn donors. Patients with hematopoietic malignancy at high-risk for relapse or with advanced disease will receive myeloablative conditioning with cyclophosphamide (Cy),low dose fludarabine (Flu) and total body irradiation (TBI) with post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.

  Eligibility

Ages Eligible for Study:   4 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 4 - 50 years
  • Patient should not have a related or unrelated volunteer donor that is suitably HLA matched and available in the required time period or be a suitable candidate for an autologous stem cell transplant.
  • Patients will have one of the following hematological malignancies: Acute myelogenous leukemia (AML):

    • Complete first remission (CR1) at high risk for relapse as defined by:

known prior diagnosis of myelodysplasia (MDS); or therapy related AML; or White cell count at presentation > 100,000; or Presence of extramedullary leukemia at diagnosis; or Unfavorable FAB type (M0, M5-7); or High-risk cytogenetics (such as those associated with MDS, abnormalities of 5, 7, 8, Philadelphia chromosome, complex karyotype); or High risk molecular markers such as FLT3 mutations; or Requirement for 2 or more inductions to achieve CR1

  • Complete second CR (CR2).

    • Acute lymphoblastic leukemia (ALL):

  • Complete first remission (CR1) at high risk for relapse as defined by:

White cell count at presentation as follows:

  • > 100,000 if < 18 years
  • > 50,000 if > 18 years; or

Presence of extensive extra-medullary disease (excluding CNS disease); or Presence of high-risk cytogenetic abnormality such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23), t(8;14) [excluding B-ALL in pediatric patients]; or

Failed to achieve complete remission after four weeks of induction therapy Unable to receive required consolidation chemotherapy as would be needed to maintain remission

  • Complete second or third remission (CR2 or CR3)

    • Acute undifferentiated leukemia (AUL), infant leukemia, or biphenotypic leukemia in CR1, CR2 or CR3. Patients with infant leukemia must be eligible to receive total body irradiation.
    • Juvenile Myelomonocytic leukemia (JMML) with < 30% bone marrow blasts.
    • Chronic myelogenous leukemia (CML)
  • GleevecTM failure in 1st or 2nd chronic phase;
  • Gleevec failure in 1st or 2nd accelerated phase.

    • Myelodysplastic Syndrome (MDS) with one of the following:

  • Low (Score 0) International Prognostic Scoring System (IPSS) score with Life-threatening cytopenia(s); or Red cell or platelet transfusion dependent
  • Intermediate (Score 1) or High (Score 2) International Prognostic Scoring System (IPSS) score.
  • Patients with bone marrow blasts > 10% should have AML induction therapy with disease response to < 5% blasts and at least partial count recovery.

    • Non-Hodgkin's Lymphoma

  • Patients with high-grade disease following initial therapy and are not appropriate for further chemotherapy or autologous stem cell transplantation.
  • Patients with high-grade or diffuse large cell NHL with recurrent disease after first remission and must have:

Chemo-sensitivity as evidenced by > partial remission (PR) (defined as > 50% reduction in mass size after therapy).

  • Patients with adequate organ function and performance status criteria as measured by:
  • Karnofsky score > or = to 70 % or Lansky score > or = to 70%
  • Renal: Calculated creatinine clearance > or = to 60 ml/min
  • Hepatic: Total bilirubin < 2.5 mg/dL unless benign congenital hyperbilirubinemia (Gilbert's syndrome) and ALT/AST < 3 x upper limit of normal
  • Albumin > or = to 2.5
  • Pulmonary: Pulmonary function (spirometry and corrected DLCO) > or = to 60% normal if available (in small children use History and Physical and CT scan as necessary to determine pulmonary status)
  • Cardiac: Left ventricular ejection fraction > or = to 50%
  • Double Unit Umbilical Cord Blood Grafts:

Units will be selected based on the HLA match to the patient and on the basis of the individual and combined cell doses of the units.

  • Patient has a related or unrelated volunteer donor that is suitably HLA matched and available in the required time period.
  • Patient is a candidate for an autologous stem cell transplant.
  • Active CNS leukemia.
  • Acute Myelogenous Leukemia in greater than CR2.
  • Acute Myelogenous Leukemia evolved from myelofibrosis.
  • Acute Lymphoblastic Leukemia, acute undifferentiated leukemia, biphenotypic leukemia or infant leukemia greater than CR3.
  • Any acute leukemia with:

    • Morphologic relapse or persistent disease in the BM (cytogenetic relapse without morphologic evidence of relapse or cytogenetic persistent disease in the BM is acceptable); or
    • Active extra-medullary leukemia; or
    • Requiring greater than 2 cycles of chemotherapy to obtain present remission status;
  • Bone Marrow aplasia (defined as BM cellularity less than 5% at transplant work-up); or
  • MDS with greater than 10% bone marrow blasts refractory to chemotherapy; or
  • CML in blast crisis; or
  • NHL refractory to chemotherapy (less than PR after 2 or more regimens); or
  • Prior autologous or allogeneic HSC transplant at any time; or
  • Prior radiation therapy rendering patient ineligible for TBI; or
  • Uncontrolled viral, bacteria or fungal infection at time of study enrollment; or
  • Seropositive or NAT positive for HIV; or
  • Females who are pregnant or breast feeding; or
  • Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00597519

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Juliet Barker, MBBS Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00597519     History of Changes
Obsolete Identifiers: NCT00388102
Other Study ID Numbers: 06-014, CA23766
Study First Received: December 26, 2007
Last Updated: September 18, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:
Cancer
Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Total Body Irradiation
Umbilical Cord Blood Grafts
06-014

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Preleukemia
Lymphoma, Non-Hodgkin
Lymphoma
Leukemia
Syndrome
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Disease
Pathologic Processes
Cyclophosphamide
Fludarabine phosphate
Mycophenolate mofetil
Fludarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014